As high-circulating Ang-2 levels are associated with poor prognosis, addition of the Ang-1 and Ang-2-neutralizing peptibody trebananib to the sorafenib treatment could improve the survival of advanced HCC patients. This evidence concerns the gene ANGPT2 and hepatocellular carcinoma.